- Home
- DCTH vs RGNX Comparison
DCTH vs RGNX Comparison
Compare DCTH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- RGNX
- Stock Information
- Founded
- DCTH 1988
- RGNX 2008
- Country
- DCTH United States
- RGNX United States
- Employees
- DCTH N/A
- RGNX N/A
- Industry
- DCTH Medical/Dental Instruments
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCTH Health Care
- RGNX Health Care
- Exchange
- DCTH Nasdaq
- RGNX Nasdaq
- Market Cap
- DCTH 388.3M
- RGNX 451.1M
- IPO Year
- DCTH N/A
- RGNX 2015
- Fundamental
- Price
- DCTH $10.67
- RGNX $9.09
- Analyst Decision
- DCTH Strong Buy
- RGNX Strong Buy
- Analyst Count
- DCTH 4
- RGNX 8
- Target Price
- DCTH $24.50
- RGNX $28.50
- AVG Volume (30 Days)
- DCTH 485.5K
- RGNX 535.6K
- Earning Date
- DCTH 11-07-2025
- RGNX 11-05-2025
- Dividend Yield
- DCTH N/A
- RGNX N/A
- EPS Growth
- DCTH N/A
- RGNX N/A
- EPS
- DCTH 0.06
- RGNX N/A
- Revenue
- DCTH $70,240,000.00
- RGNX $155,782,000.00
- Revenue This Year
- DCTH $159.22
- RGNX $203.27
- Revenue Next Year
- DCTH $41.22
- RGNX $0.58
- P/E Ratio
- DCTH $193.75
- RGNX N/A
- Revenue Growth
- DCTH 491.35
- RGNX 74.95
- 52 Week Low
- DCTH $8.08
- RGNX $5.04
- 52 Week High
- DCTH $18.23
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- DCTH 43.30
- RGNX 50.36
- Support Level
- DCTH $10.60
- RGNX $9.35
- Resistance Level
- DCTH $11.38
- RGNX $10.08
- Average True Range (ATR)
- DCTH 0.44
- RGNX 0.54
- MACD
- DCTH 0.01
- RGNX -0.01
- Stochastic Oscillator
- DCTH 5.26
- RGNX 30.77
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.